{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:51:55Z","timestamp":1791571915807,"version":"4.3.4"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:p>\n                    Rheumatoid arthritis (RA) is associated with increased risks of osteoporosis and fracture. Amorphous calcium carbonate (ACC) may enhance osteogenic differentiation and increase bone mineral density (BMD). The effects of ACC supplementation on BMD and bone turnover markers (BTMs) in RA have not been explored. This study investigated the influence of ACC supplementation on BMD, BTMs, and the risk of osteoporotic fractures in RA patients. We enrolled 67 RA patients with osteopenia or osteoporosis. BMD was measured by dual-energy X-ray absorptiometry before and after 1 year of ACC supplementation, providing elemental calcium 800\u2009mg\/day combined with vitamin D3 400 IU\/day. Serum levels of N-terminal propeptide of type I collagen and C-terminal cross-linking telopeptide were measured at baseline and every 3 months following ACC supplementation. The 10-year fracture probability was calculated using the Fracture Risk Assessment Tool (FRAX\u00ae), and RA activity was assessed using the 28-joint disease activity score. Multivariate regression analysis revealed that age and corticosteroid dosage \u22655\u2009mg were significant risk factors for major osteoporotic fracture. The 28-joint disease activity scores were inversely correlated with BMD of the right femoral neck (\n                    <jats:italic toggle=\"yes\">r<\/jats:italic>\n                    \u2005=\u2005\u22120.426,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) and left femoral neck (\n                    <jats:italic toggle=\"yes\">r<\/jats:italic>\n                    \u2005=\u2005\u22120.383,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.005). After 12 months of ACC supplementation, bilateral femoral neck BMD increased significantly (from 0.61 to 0.63\u2009g\/cm\n                    <jats:sup>2<\/jats:sup>\n                    , both\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), accompanied by improvement in T-scores. Serum levels of N-terminal propeptide of type I collagen and C-terminal cross-linking telopeptide were significantly decreased (mean 53.42 vs 41.24\u2009ng\/mL,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001; 0.29 vs 0.25\u2009ng\/mL,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05, respectively). Twelve-month ACC supplementation increased bilateral femoral neck BMD and reduced BTM levels in RA patients, particularly in anti-citrullinated peptide antibody\u2013positive patients.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047846","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:03:18Z","timestamp":1773043398000},"page":"e47846","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Amorphous calcium carbonate supplementation and bone outcomes in rheumatoid arthritis: A prospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Wei-Sheng","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Allergy, Rheumatology and Immunology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ku","family":"Chen","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2821-6597","authenticated-orcid":false,"given":"Chun-Kai","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Food Science, National Taiwan Ocean University, Keelung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Cheng","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Allergy, Rheumatology and Immunology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Youh","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Immunology and Rheumatology, Department of Medicine, Fu Jen Catholic University Hospital and College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Tei","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Allergy, Rheumatology and Immunology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"PhD Program in Translational Medicine and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chung","family":"Huang","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-2235","authenticated-orcid":false,"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan"},{"name":"College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis.","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","article-title":"Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions.","volume":"18","author":"Komatsu","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20261009","first-page":"147","article-title":"Exploring the causal relationship between osteoporosis and rheumatoid arthritis: a bidirectional Mendelian randomization study.","volume":"17","author":"Li","year":"2025","journal-title":"Orthop Res Rev"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"e004564","DOI":"10.1136\/rmdopen-2024-004564","article-title":"Significant decrease of osteoporosis and osteoporotic fractures in rheumatoid arthritis within a period of 24 years: experiences of a single centre.","volume":"10","author":"Oelzner","year":"2024","journal-title":"RMD Open"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.semarthrit.2015.04.014","article-title":"Evolutionary medicine and bone loss in chronic inflammatory diseases--a theory of inflammation-related osteopenia.","volume":"45","author":"Straub","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","article-title":"Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.","volume":"27","author":"Balasubramanian","year":"2016","journal-title":"Osteoporos Int"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00198-019-04966-z","article-title":"Increased risk of osteoporotic vertebral fracture in rheumatoid arthritis patients with new-onset cardiovascular diseases: a retrospective nationwide cohort study in Taiwan.","volume":"30","author":"Hong","year":"2019","journal-title":"Osteoporos Int"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","article-title":"Biologic therapies and bone loss in rheumatoid arthritis.","volume":"28","author":"Zerbini","year":"2017","journal-title":"Osteoporos Int"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"e0188454","DOI":"10.1371\/journal.pone.0188454","article-title":"Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jbmr.1489","article-title":"Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.","volume":"27","author":"Kim","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10067-023-06735-0","article-title":"Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis.","volume":"43","author":"Chen","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0341","article-title":"Osteoporosis and rheumatoid arthritis: a review of current understanding and practice.","volume":"85","author":"Kirkham-Wilson","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"R16-20261009","first-page":"290","article-title":"A potent calcium dietary consumption improves bone mineral density in Asian older adults.","volume":"9","author":"Yoon","year":"2025","journal-title":"J Family Med Prim Care Open Acc"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"10817","DOI":"10.1039\/D0FO00787K","article-title":"Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.","volume":"11","author":"Liu","year":"2020","journal-title":"Food Funct"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jbmr.196","article-title":"Solubility and bioavailability of stabilized amorphous calcium carbonate.","volume":"26","author":"Meiron","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/jbmr.2255","article-title":"Increased calcium absorption from synthetic stable amorphous calcium carbonate: a double-blind randomized crossover clinical trial in postmenopausal women.","volume":"29","author":"Vaisman","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4236\/health.2013.57A2003","article-title":"Bone loss prevention in ovariectomized rats using stable amorphous calcium carbonate.","volume":"05","author":"Shaltiel","year":"2013","journal-title":"Health"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/jbmr.2255","article-title":"Increased calcium absorption from synthetic stable amorphous calcium carbonate: double-blind randomized crossover clinical trial in postmenopausal women.","volume":"29","author":"Vaisman","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R22-20261009","first-page":"146","article-title":"Amorphous calcium carbonate enhances osteogenic differentiation and myotube formation of human bone marrow derived mesenchymal stem cells and primary skeletal muscle cells under microgravity conditions.","volume":"41","author":"Cohen","year":"2024","journal-title":"Life Sci Space Res"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative.","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R24-20261009","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.","volume":"843","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK.","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"R27-20261009","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jfma.2016.03.006","article-title":"Establishing and evaluating FRAX\u00ae probability thresholds in Taiwan.","volume":"116","author":"Chan","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"R28-20261009","doi-asserted-by":"crossref","first-page":"44588","DOI":"10.1038\/s41598-025-28252-7","article-title":"Two-year outcomes of denosumab treatment for osteoporosis comparing effects of calcium and vitamin D supplementation.","volume":"15","author":"Cho","year":"2025","journal-title":"Sci Rep"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"E1333","DOI":"10.1503\/cmaj.221647","article-title":"Clinical practice guideline for management of osteoporosis in Canada.","volume":"195","author":"Morin","year":"2023","journal-title":"CMAJ"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S2213-8587(24)00225-0","article-title":"Osteopenia: a key target for fracture prevention.","volume":"12","author":"Reid","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.afos.2024.02.001","article-title":"Asia-Pacific consensus on long-term and sequential therapy for osteoporosis.","volume":"10","author":"Tai","year":"2024","journal-title":"Osteoporos Sarcopenia"},{"key":"R32-20261009","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00198-020-05360-w","article-title":"Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis.","volume":"31","author":"Wang","year":"2020","journal-title":"Osteoporos Int"},{"key":"R33-20261009","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/jim-2018-000723","article-title":"The impact of low-dose glucocorticoids on disease activity, bone mineral density, fragility fractures, and 10-year probability of fractures in patients with rheumatoid arthritis.","volume":"66","author":"Cheng","year":"2018","journal-title":"J Investig Med"},{"key":"R34-20261009","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.3390\/ijms23158740","article-title":"Mechanisms of systemic osteoporosis in rheumatoid arthritis.","volume":"23","author":"Pietschmann","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R35-20261009","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10067-024-06932-5","article-title":"The interplay of rheumatoid arthritis and osteoporosis: exploring the pathogenesis and pharmacological approaches.","volume":"43","author":"Gupta","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R36-20261009","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00296-020-04593-6","article-title":"Osteoporosis in patients with rheumatoid arthritis: trends in the German national database 2007-2017.","volume":"40","author":"Lindner","year":"2020","journal-title":"Rheumatol Int"},{"key":"R37-20261009","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/ard.61.12.1085","article-title":"Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo rheumatoid arthritis register.","volume":"61","author":"Haugeberg","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R38-20261009","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40279-021-01496-9","article-title":"Effects of spaceflight on musculoskeletal health: a systematic review and meta-analysis, considerations for interplanetary travel.","volume":"51","author":"Comfort","year":"2021","journal-title":"Sports Med"},{"key":"R39-20261009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2015.12.057","article-title":"The impact of microgravity on bone in humans.","volume":"87","author":"Grimm","year":"2016","journal-title":"Bone"},{"key":"R40-20261009","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12018-011-9092-8","article-title":"Ionizing radiation and bone loss: space exploration and clinical therapy applications.","volume":"9","author":"Willey","year":"2011","journal-title":"Clin Rev Bone Miner Metab"},{"key":"R41-20261009","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13075-016-1116-9","article-title":"Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.","volume":"18","author":"Bugatti","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R42-20261009","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00296-017-3674-9","article-title":"Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients.","volume":"37","author":"Llorente","year":"2017","journal-title":"Rheumatol Int"},{"key":"R43-20261009","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI60975","article-title":"Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin.","volume":"122","author":"Harre","year":"2012","journal-title":"J Clin Invest"},{"key":"R44-20261009","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/ard.2003.016253","article-title":"Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density.","volume":"63","author":"Lodder","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R45-20261009","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00198-012-2073-z","article-title":"Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?","volume":"24","author":"Van Der Goes","year":"2013","journal-title":"Osteoporos Int"},{"key":"R46-20261009","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis.","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"R47-20261009","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2005.12.020","article-title":"Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?","volume":"119","author":"Bonnick","year":"2006","journal-title":"Am J Med"},{"key":"R48-20261009","doi-asserted-by":"crossref","first-page":"1628434","DOI":"10.3389\/fendo.2025.1628434","article-title":"Bone turnover markers (\u03b2-CTX, PINP, ALP) in osteoporosis: diagnosis and monitoring.","volume":"16","author":"Wu","year":"2025","journal-title":"Front Endocrinol"},{"key":"R49-20261009","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: national bone health alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:09:28Z","timestamp":1791569368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047846","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2025-08-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}